New cancer clinical trial: Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Published on: March 27, 2018 at 12:00PM
Condition:   Neuroendocrine Tumors
Interventions:   Drug: 177Lu-DOTA-EB-TATE 1;   Drug: 177Lu-DOTA-TATE;   Drug: 177Lu-DOTA-EB-TATE 2
Sponsors:   Peking Union Medical College Hospital;   National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Recruiting
https://ift.tt/2pL4AoG